Market Intelligence, Clinical Progress, and High-Purity Reagents for Spinocerebellar Ataxia Type 3 (SCA3) Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ATXN3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT & Mutant) | ATXN3 Wild-Type and PolyQ-Expanded Recombinant Proteins High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. Theoretical MW confirmed. WT (Q26-30), Mutant (Q71-78) available. |
View ATXN3 Products |
| Gene Delivery | ATXN3 Promise-ORF / Lentivirus Full-length ORF (WT and pathogenic expansion) for stable neuronal cell lines. CMV/EF1a promoter. |
View ATXN3 Products |
| Benchmark Ab | Anti-ATXN3 Recombinant Antibody Research-grade positive control for Western Blot, ICC, and Co-IP. Sequence Verified. |
View ATXN3 Products |
| Validator | ATXN3 siRNA Set (3 unique sequences) For knockdown and specificity verification in cell-based assays. |
View ATXN3 Products |
| Related Target A | HTT (Huntingtin) Shared pathogenic mechanism (Polyglutamine/PolyQ expansion); parallel target for cross-screening. |
View HTT Products |
| Related Target B | VCP (p97) Direct binding partner of ATXN3 in ERAD pathway; key interactor for co-IP and PPI assays. |
View VCP Products |
| Related Target C | ATXN1 (Ataxin-1) Parallel SCA1 pathway target, polyglutamine disease comparator. |
View ATXN1 Products |
| Related Target D | ATXN2 (Ataxin-2) SCA2 target; ALS/SCA3 overlap biology, stress granule component. |
View ATXN2 Products |
| Related Target E | RAD23B Proteasomal shuttle protein; partner in ATXN3-mediated substrate routing. |
View RAD23B Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Evaluating mutant-specific degraders/inhibitors | Recombinant WT and PolyQ-expanded ATXN3 proteins available with >95% purity and Theoretical MW strictly verified. |
| Testing ASO/siRNA knockdown efficiency in CNS models | Premade Lentivirus for robust, stable expression of ATXN3 in hard-to-transfect neural lineages. |
| Lack of Controls | Sequence Verified anti-ATXN3 antibodies included for robust Western Blot/IHC target tracking. |
| False Positives / Off-target binding | Validated siRNA included for specificity checks and target-dependency validation; Endotoxin controlled (<1 EU/µg). |
| PolyQ Length-Dependent Aggregation | Defined repeat length proteins (Q26, Q44, Q78) with purity >95%, monodisperse by SEC. |
| DUB Activity Retention | Active Josephin domain proteins expressed in HEK293, native glycosylation pattern preserved; suitable for Ub-AMC assays. |
| Allele-Specific Drug Screening | Matched WT vs Mutant protein pairs available for selectivity assays. |
| Cellular Aggregate Modeling | Lentivirus with expanded CAG repeats for stable inclusion body formation in neuronal cells. |
| Target Engagement Validation | Validated siRNA and Lentivirus-ORF for qPCR/Western knockdown and overexpression standards. |
Live ATXN3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Polyglutamine Research & Pathogenesis
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for ATXN3 therapeutics is intensifying, driven by the urgent unmet medical need in Spinocerebellar Ataxia Type 3 (SCA3), also known as Machado-Joseph Disease (MJD). Because the disease is triggered by a toxic gain-of-function from polyglutamine (polyQ) expansions, major players are shifting focus from symptomatic small molecules to genetic silencing modalities (ASOs, siRNAs, and AAV-delivered miRNAs). As first-generation non-allele-specific therapies navigate clinical safety, the next wave of R&D is strictly targeting allele-specific silencing or utilizing Targeted Protein Degradation (PROTACs/AUTACs) to selectively clear the mutant ATXN3 protein while sparing wild-type physiological deubiquitinase functions. Additionally, improvements in blood-brain barrier penetration and intrathecal delivery are critical for CNS efficacy. Leading programs include Vico Therapeutics' VO659 (allele-specific ASO targeting CAG repeats) and uniQure's AMT-116 (AAV-delivered miRNA), which recently received FDA Orphan Drug Designation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antisense Oligonucleotides (ASO) | Vico Therapeutics, Biogen/Ionis | Spinocerebellar Ataxia Type 3 (SCA3) | In vitro Knockdown Validation (Need High-titer Lentivirus for stable cell lines) |
| Gene Therapy (AAV-miRNA) | uniQure | Spinocerebellar Ataxia Type 3 (SCA3) | Target Engagement (Need Sequence Verified Antibodies for precise expression monitoring) |
| Small Molecule DUB Inhibitors | Academic Consortia, BioBlast Pharma | Polyglutamine Diseases | Enzymatic Activity Assay (Need active Josephin domain proteins for Ub-AMC assays) |
| Targeted Protein Degraders (PROTACs) | Emerging Biotech | SCA3 | Selectivity Assay (Need precisely engineered PolyQ Mutant vs WT Recombinant Proteins for SPR/ternary complex) |